Capital Counsel LLC NY boosted its holdings in Celgene Corporation (NASDAQ:CELG) by 0.4% during the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 1,649 shares of the biopharmaceutical company’s stock after buying an additional 6 shares during the period. Capital Counsel LLC NY’s holdings in Celgene Corporation were worth $214,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Thompson Davis & CO. Inc. raised its holdings in Celgene Corporation by 5.9% in the second quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 43 shares during the period. Weatherstone Capital Management raised its holdings in Celgene Corporation by 28.6% in the second quarter. Weatherstone Capital Management now owns 3,331 shares of the biopharmaceutical company’s stock valued at $433,000 after buying an additional 741 shares during the period. Jackson Wealth Management LLC raised its holdings in Celgene Corporation by 12.6% in the second quarter. Jackson Wealth Management LLC now owns 13,933 shares of the biopharmaceutical company’s stock valued at $1,884,000 after buying an additional 1,559 shares during the period. Jacobi Capital Management LLC raised its holdings in Celgene Corporation by 4.3% in the second quarter. Jacobi Capital Management LLC now owns 2,569 shares of the biopharmaceutical company’s stock valued at $339,000 after buying an additional 105 shares during the period. Finally, Johnson Financial Group Inc. raised its holdings in Celgene Corporation by 10.3% in the second quarter. Johnson Financial Group Inc. now owns 8,645 shares of the biopharmaceutical company’s stock valued at $1,123,000 after buying an additional 810 shares during the period. Hedge funds and other institutional investors own 79.16% of the company’s stock.

Several research firms recently commented on CELG. Mizuho restated a “buy” rating on shares of Celgene Corporation in a report on Friday, November 3rd. Oppenheimer Holdings, Inc. reaffirmed a “buy” rating and issued a $166.00 price objective (up previously from $163.00) on shares of Celgene Corporation in a research report on Monday, October 30th. Cantor Fitzgerald reaffirmed a “hold” rating and issued a $112.00 price objective on shares of Celgene Corporation in a research report on Monday, October 30th. J P Morgan Chase & Co set a $123.00 price objective on shares of Celgene Corporation and gave the company a “buy” rating in a research report on Friday, October 27th. Finally, UBS AG lowered their price objective on shares of Celgene Corporation from $146.00 to $120.00 and set a “buy” rating for the company in a research report on Friday, October 27th. One equities research analyst has rated the stock with a sell rating, eleven have given a hold rating, nineteen have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $139.64.

Shares of Celgene Corporation (CELG) opened at $98.86 on Wednesday. The company has a quick ratio of 3.52, a current ratio of 3.65 and a debt-to-equity ratio of 1.31. The stock has a market capitalization of $79,644.98, a price-to-earnings ratio of 15.81, a price-to-earnings-growth ratio of 0.78 and a beta of 1.79. Celgene Corporation has a one year low of $94.55 and a one year high of $147.17.

Celgene Corporation (NASDAQ:CELG) last posted its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.87 by $0.04. The company had revenue of $3.29 billion for the quarter, compared to analysts’ expectations of $3.42 billion. Celgene Corporation had a return on equity of 63.80% and a net margin of 27.36%. The firm’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same period last year, the business posted $1.58 earnings per share. equities research analysts anticipate that Celgene Corporation will post 6.67 EPS for the current fiscal year.

In related news, insider Terrie Curran sold 1,727 shares of Celgene Corporation stock in a transaction dated Monday, September 25th. The shares were sold at an average price of $143.89, for a total transaction of $248,498.03. Following the sale, the insider now directly owns 3,925 shares in the company, valued at $564,768.25. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Gilla Kaplan sold 9,250 shares of Celgene Corporation stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $141.56, for a total transaction of $1,309,430.00. Following the sale, the director now owns 85,551 shares in the company, valued at $12,110,599.56. The disclosure for this sale can be found here. Insiders sold 20,227 shares of company stock worth $2,843,956 over the last quarter. 0.95% of the stock is currently owned by company insiders.

COPYRIGHT VIOLATION NOTICE: “Capital Counsel LLC NY Boosts Position in Celgene Corporation (CELG)” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another domain, it was copied illegally and republished in violation of US and international copyright law. The legal version of this news story can be accessed at https://www.thecerbatgem.com/2017/11/15/capital-counsel-llc-ny-boosts-position-in-celgene-corporation-celg.html.

Celgene Corporation Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Stock Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related stocks with our FREE daily email newsletter.